Korsuva
Drug Korsuva is a Kappa opioid receptor agonist for pruritus associated with kidney disease (CKD-aP)
NDC 59353-065-12
General payments
$81,617
Research payments
$0
Through program year 2022, $81,617 in general payments and $0 in research payments were reported against Korsuva (Korsuva is a Kappa opioid receptor agonist for pruritus associated with kidney disease (CKD-aP)).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | General | $81,617 | 1,878 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2022.
The top 5 of 28 specialties; each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.
The top 5 of 43 states; each share is of general payments naming this product in 2022 where a state was reported.
Records
1,878 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.